Summary Slides & Reports
Summary Slides - Outcomes After HCT / ACT
Using information from our outcomes database, CIBMTR annually prepares and distributes charts summarizing current uses and outcomes of allogeneic and autologous hematopoietic cell transplantation (HCT); adoptive cellular therapies (ACT), including chimeric antigen receptor T-cell (CAR-T) therapy; and patient-reported outcomes (PRO).
The US Summary Slides are an annual report on data submitted to CIBMTR by centers in the US and describe information related to practices and general survival outcomes after HCT / ACT. The current edition includes treatments performed prior to 2024.
The PRO Summary Slides report data collected directly from patients through CIBMTR’s PRO Protocol. CIBMTR began collecting PRO in 2020, and by October 2023, CIBMTR was enrolling patients from 30 centers. These PRO Summary Slides report data from 2020-2023.
- Download the 2024 US Summary Slides (PowerPoint)
- To cite the US Summary Slides
Citation: Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - A report from the CIBMTR. Transplant Cell Ther. 2025 Aug;31(8):505-532. doi:10.1016/j.jtct.2025.05.014. Epub 2025 May 19. PMC12302970. -
Slides 3 to 49
Exhibit data on frequency of transplants according to transplant and CAR–T infusion type, donor, patient age, graft source, graft-versus-host disease (GVHD)prophylaxis, disease, causes of death, conditioning regimen, and race and/or ethnicity. All frequencies represent first autologous and allogeneic transplants and CAR-T infusions registered with CIBMTR during the period. -
Slides 50 to 69
Include overall survival outcomes according to age, donor type, disease, disease status, year of infusion, race and ethnicity. Comparisons across survival curves are univariate and do not adjust for all potentially important factors; consequently, results should be interpreted cautiously.
- To cite the US Summary Slides
*Slides are also availabe upon request by contacting info-request@mcw.edu
US Transplant and Survival Statistics on Related Sites
In addition to the data and resources available through this website, HCT data collected and analyzed by CIBMTR are also available through related websites.
C.W. Bill Young Cell Transplantation Program website
Autologous, Related and Unrelated Allogeneic Transplant Data
In 2006, CIBMTR was awarded a contract from the Health Resources and Services Administration of the U.S. Department of Health and Human Services to administer the Stem Cell Therapeutic Outcomes Database (SCTOD) of the C.W. Bill Young Cell Transplantation Program.
As a part of this contract, CIBMTR provides statistics about autologous, related, and unrelated allogeneic transplants performed by U.S. transplant centers:
HRSA Transplant Activity Report
View tables reflecting the number of bone marrow and cord blood transplants performed at transplant centers in the US, by patient age, patient gender, patient race, cell source, the year when the transplant was performed, disease, donor type, and the state in which the transplant center is located.
US Patient Survival Report
View patient survival estimates for a disease and the length of time after transplant: 100 days, 1 year, and 3 years. You can also select survival estimates by patient age, patient gender, patient race, or cell source.
NMDP website
Allogeneic Transplant Data, by Transplant Center
CIBMTR performs a center-specific survival analysis each year as part of the C.W. Bill Young Cell Transplantation Program. The methodology for this analysis (click to view the previous methodology) is reviewed at the Center Outcomes Forum every other year. The results of this analysis are incorporated into a comprehensive guide of all U.S. transplant centers that perform allogeneic transplants (using related or unrelated donors). The listing includes the kinds of transplants performed, transplant outcomes, diseases treated, and general cost information for each center.
US Transplant Center Listing
Each transplant center listing includes information about facilities, personnel, diseases treated, cost, and transplant experience, including the number of transplants performed and survival rates by age, disease type, and disease stage.
Publication Permission Request
Please note that a permission request is subject to the following conditions:
Required Public Use Statement
If used publicly, the following statement must be included: “The views expressed in this article are those of the authors and do not reflect the position of the Center for International Blood and Marrow Transplant Research.”
Permissions for New Editions or Updates
CIBMTR material shall be used only in the manner as described above. If CIBMTR material is sought for inclusion in a new edition or updated version to a document or publication from which copyright permission is currently being sought, a new CIBMTR Copyright Permission Request Form must be submitted to CIBMTR.
Restrictions on Adaptation or Modification
Except as herein provided, no adaptation of changes shall be made to CIBMTR materials without prior written consent of CIBMTR.
Required Attribution for CIBMTR Data
Appropriate credit for CIBMTR data is required.
Publication Permission Request
Use the form below to request permission to reproduce CIBMTR slides or data. Your request will receive prompt attention.